RHYTHM PHARMACEUTICALS, INC. Deferred Revenue (Non-Current)
RHYTHM PHARMACEUTICALS, INC. (RYTM) had Deferred Revenue (Non-Current) of $109.24 million as of 2024-09-30, per its 10-Q filed 2024-11-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:DeferredRevenueNoncurrent · last filed 2024-11-06
- 2024-09-30: Deferred Revenue, Noncurrent $109.24M.
- 2024-06-30: Deferred Revenue, Noncurrent $108.37M.
- 2024-03-31: Deferred Revenue, Noncurrent $107.37M.
- 2023-12-31: Deferred Revenue, Noncurrent $106.14M.
| Period end | Deferred Revenue, Noncurrent |
|---|---|
| 2024-09-30 | $109.24M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $108.37M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $107.37M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $106.14M 10-Q · filed 2024-11-06 |
| 2023-09-30 | $104.70M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $79.35M 10-Q · filed 2023-08-01 |
| 2023-03-31 | $77.52M 10-Q · filed 2023-05-02 |
| 2022-12-31 | $75.81M 10-K · filed 2024-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |